Stanford School of Medicine
Longo Lab Informatics
View the docs

Photo by Yu Wang on Unsplash

Projects

At the Longo Lab we work on a range of projects in neurodegenerative disease and human-mouse translatable bioinformatic insights

Research Overview Project Dashboards

Mice models

Several Alzheimer's Disease mouse models in our projects. See here for more information.

PS19

PS19 (B6;C3-Tg(Prnp-MAPT*P301S)PS19Vle/J) Transgenic (Tg) mice express the P301S mutant form of human tau and develop progressive accumulation of neurofibrillary tangles with age. Thus, the strain is commonly used as a model of tauopathy, such as Alzheimer's Disease.

T41B

The line 41 of mThy1-hAPPLond/swe mouse (hAPP751+) is a transgenic mouse model of AD expressing high level of human APP751 cDNA containing the London (V717I) and Swedish (K670M/N671L) mutations under the regulatory control of the murine (m)Thy-1 gene.

5XFAD

These 5XFAD transgenic mice overexpress both mutant human amyloid beta (A4) precursor protein 695 (APP) with the Swedish (K670N, M671L), Florida (I716V), and London (V717I) Familial Alzheimer's Disease (FAD) mutations and human presenilin 1 (PS1) harboring two FAD mutations, M146L and L286V. Expression of both transgenes is regulated by neural-specific elements of the mouse Thy1 promoter to drive overexpression in the brain.

R6/2

R6/2 (B6CBA-Tg(HDexon1)62Gpb/3J) mice are transgenic for the 5' end of the human HD gene carrying approximately 120 +/- 5 CAG repeat expansions (see Trinucleotide Scoring and Range below). The transgene is ubiquitously expressed.

zQ175

The zQ175 knock-in (zQ175 KI) allele has the mouse Htt exon 1 replaced by the human HTT exon 1 sequence with a ~190 CAG repeat tract (see note below). These B6J.zQ175 KI mice (Stock No. 027410) are useful for studying Huntington's disease pathogenesis and for the assessment of potential therapeutic interventions.

Drug compounds

Therapeutic compounds studied in the Longo Lab.

LM11A-C31 (C31)

C31 targets p75 neurotrophin receptor.

PTX-BD10-2 (BD10-2)

BD10-2 targets TRK neurotrophin receptors.

PTX-BD10-3 (BD10-3)

BD10-3 targets TRK neurotrophin receptors.